Table 2.

Small-molecule compounds targeting SIRT5 for cancer therapy

Name	Chemical structure	mechanism	Cancer cell type	IC50	Pharmacological interventions	Preclinical tumor model	Ref.
MC3482		MC3428-mediated SIRT5 inhibition led to an increase in intracellular ammonia and promoted ammonia-induced autophagy and mitosis	MDA-MB-231	42% inhibition of SIRT5 at 50 μM	50μM MC3482 is treated in MDA-MB-231 for 24 h. No in vivo experiment information is available.	/	95
MC3183		SIRT5-GOT1-glutamine metabolism pathway	CFPAC, FG, PANC1, S2-013, Canpan1, S2-007, T3M4, Patu8902, MIAPaCa-2, Capan2	IC50 = 25.4 - 236.9 μM	PDAC cells are treated with 10μM MC3183 for 24 h. The maximum concentration and half-life of MC3138 in plasma are approximately 230 μM and 5.059 hours, respectively. In the PDX tumor model of NOD-SCID mice, when the concentration of MC3183 in tumor tissue is around 100~200μM, the combined use of MC3183 and gemcitabine can effectively inhibit PDAC growth.	PDX models of pancreatic cancer	92
NRD167		NRD167 induced apoptosis through oxidative stress and the glutamine metabolism pathway	SKM-1 and OCI-AML2	IC50 = 5-8 μM	5-10μM in AML cells and no in vivo experiment information is available.	Xenograft mouse models using CMK and OCI-AML3 cells	119